MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel

Oncology Letters

Volumn 8, Issue 5, 2014, Pages 2193-2200

  Liu, Ronghua ^a   Liu, Xiaoming ^a   Zheng, Yijie ^a   Gu, Jie ^b   Xiong, Shudao ^a,c   Jiang, Pei ^a   Jiang, Xuechao ^a   Huang, Enyu ^a   Yang, Yixian ^a   Ge, Di ^b   Chu, Yiwei ^a  

^a FUDAN UNIVERSITY   (China)

^b ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Drug resistance; EGFR; Lung cancer; MicroRNA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MICRORNA 7; PACLITAXEL; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; MTT ASSAY; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84907151698     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2500     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Gu J, Ding JY, Lu CL, et al: Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer 81: 259-265, 2013.
3. Edelman MJ: Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. Clin Lung Cancer 10: S30-S34, 2009.
4. Morales-Cano D, Calviño E, Rubio V, et al: Apoptosis induced by paclitaxel via Bcl-2, Bax and caspases 3 and 9 activation in NB4 human leukaemia cells is not modulated by ERK inhibition. Exp Toxicol Pathol 65: 1101-1108, 2013.
5. Kavallaris M: Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10: 194-204, 2010.
6. Wan YF, Guo XQ, Wang ZH, Ying K and Yao MH: Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin 25: 378-384, 2004.
7. Xu R, Sato N, Yanai K, et al: Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells. Anticancer Res 29: 261-270, 2009.
8. Kastl L, Brown I and Schofield AC: Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells. Int J Oncol 36: 1235-1241, 2010.
9. Le XF and Bast RC Jr: Src family kinases and paclitaxel sensitivity. Cancer Biol Ther 12: 260-269, 2011.
10. Modok S, Mellor HR and Callaghan R: Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6: 350-354, 2006.
11. Lujambio A and Lowe SW: The microcosmos of cancer. Nature 482: 347-355, 2012.
12. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
13. Jiang P, Liu R, Zheng Y, et al: MiR-34a inhibits lipopolysaccharide-induced inflammatory response through targeting Notch1 in murine macrophages. Exp Cell Res 318: 1175-1184, 2012.
14. Zheng Y, Xiong S, Jiang P, et al: Glucocorticoids inhibit lipopolysaccharide-mediated inflammatory response by downregulating microRNA-155: a novel anti-inflammation mechanism. Free Radic Biol Med 52: 1307-1317, 2012.
15. Haenisch S and Cascorbi I: miRNAs as mediators of drug resistance. Epigenomics 4: 369-381, 2012.
16. Schoof CR, Botelho EL, Izzotti A and Vasques Ldos R: MicroRNAs in cancer treatment and prognosis. Am J Cancer Res 2: 414-433, 2012.
17. Miller TE, Ghoshal K, Ramaswamy B, et al: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283: 29897-29903, 2008.
18. Takwi AA, Wang YM, Wu J, et al: miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells. Oncogene 2013.
19. Yang SM, Huang C, Li XF, Yu MZ, He Y and Li J: miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology 306: 162-168, 2013.
20. Pan YZ, Morris ME and Yu AM: MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 75: 1374-1379, 2009.
21. Liang Z, Wu H, Xia J, et al: Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 79: 817-824, 2010.
22. Kastl L, Brown I and Schofield AC: miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat 131: 445-454, 2012.
23. Xiong S, Zheng Y, Jiang P, Liu R, Liu X and Chu Y: MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci 7: 805-814, 2011.
24. Xiong S, Zheng Y, Jiang P, Liu R, Liu X, Qian J, Gu J, Chang L, Ge D and Chu Y: PA28gamma emerges as a novel functional target of tumor suppressor microRNA-7 in non-small-cell lung cancer. Br J Cancer 110: 353-362, 2014.
25. Nordentoft I, Birkenkamp-Demtroder K, Agerbæk M, et al: miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics 5: 40, 2012.
26. Tian W, Chen J, He H and Deng Y: MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications. Clin Transl Oncol 15: 335-342, 2013.
27. Zhang Y, Hu H, Song L, Cai L, Wei R and Jin W: Epirubicin-mediated expression of miR-302b is involved in osteosarcoma apoptosis and cell cycle regulation. Toxicol Lett 222: 1-9, 2013.
28. Costa PM, Cardoso AL, Nóbrega C, et al: MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma. Hum Mol Genet 22: 904-918, 2013.
29. Duncavage E, Goodgame B, Sezhiyan A, Govindan R and Pfeifer J: Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J Thorac Oncol 5: 1755-1763, 2010.
30. Rai K, Takigawa N, Ito S, et al: Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther 10: 1720-1727, 2011.
31. Kefas B, Godlewski J, Comeau L, et al: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68: 3566-3572, 2008.
32. Webster RJ, Giles KM, Price KJ, et al: Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 284: 5731-5741, 2009.
33. Chou YT, Lin HH, Lien YC, et al: EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res 70: 8822-8831, 2010.
34. Merlo V, Longo M, Novello S and Scagliotti GV: EGFR pathway in advanced non-small cell lung cancer. Front Biosci (Schol Ed) 3: 501-517, 2011.
35. Petitprez A and Larsen AK: Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models. Curr Pharm Des 19: 958-964, 2013.
36. Rekhtman N, Paik PK, Arcila ME, et al: Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 18: 1167-1176, 2012.
37. Tanaka K, Babic I, Nathanson D, et al: Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov 1: 524-538, 2011.
38. Lee KM, Choi EJ and Kim IA: microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol 101: 171-176, 2011.